Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 26;14(8):1915-1923.
doi: 10.1093/ckj/sfaa233. eCollection 2021 Aug.

Survival with low- and high-flux dialysis

Emilio Sánchez-Álvarez  1 , Minerva Rodríguez-García  2 , Francesco Locatelli  3 , Carmine Zoccali  4 , Alejandro Martín-Malo  5 , Jürgen Floege  6 , Markus Ketteler  7 , Gerard London  8 , José L Górriz  9   10 , Boleslaw Rutkowski  11 , Anibal Ferreira  12 , Drasko Pavlovic  13 , Jorge B Cannata-Andía  14 , José L Fernández-Martín  13 ; COSMOS group
Affiliations

Survival with low- and high-flux dialysis

Emilio Sánchez-Álvarez et al. Clin Kidney J. .

Abstract

Background: Besides advances in haemodialysis (HD), mortality rates are still high. The effect of the different types of HD membranes on survival is still a controversial issue. The aim of this COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis was to survey, in HD patients, the relationship between the use of conventional low- or high-flux membranes and all-cause and cardiovascular mortality.

Methods: COSMOS is a multicentre, open-cohort, 3-year prospective study, designed to evaluate mineral and bone disorders in the European HD population. The present analysis included 5138 HD patients from 20 European countries, 3502 randomly selected at baseline (68.2%), plus 1636 new patients with <1 year on HD (31.8%) recruited to replace patients who died, were transplanted, switched to peritoneal dialysis or lost to follow-up by other reasons. Cox-regression analysis with time-dependent variables, propensity score matching and the use of an instrumental variable (facility-level analysis) were used.

Results: After adjustments using three different multivariate models, patients treated with high-flux membranes showed a lower all-cause and cardiovascular mortality risks {hazard ratio (HR) = 0.76 [95% confidence interval (CI) 0.61-0.96] and HR = 0.61 (95% CI 0.42-0.87), respectively}, that remained significant after matching by propensity score for all-cause mortality (HR = 0.69, 95% CI 0.52-0.93). However, a facility-level analysis showed no association between the case-mix-adjusted facility percentage of patients dialysed with high-flux membranes and all-cause and cardiovascular mortality.

Conclusions: High-flux dialysis was associated with a lower relative risk of all-cause and cardiovascular mortality. However, dialysis facilities using these dialysis membranes to a greater extent did not show better survival.

Keywords: chronic haemodialysis; dialysis; dialysis membranes; mortality; mortality risk.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Number of patients included and excluded in this study.
FIGURE 2:
FIGURE 2:
HRs of unadjusted relative all-cause and cardiovascular mortalities in different subgroups of patients treated with high-flux HD compared with low-flux HD.
See this image and copyright information in PMC

References

    1. Robinson BM, Akizawa T, Jager KJ. et al. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 2016; 388: 294–306 - PMC - PubMed
    1. Kramer A, Stel V, Zoccali C. et al. An update on renal replacement therapy in Europe: ERA-EDTA registry data from 1997 to 2006. Nephrol Dial Transplant 2009; 24: 3557–3566 - PubMed
    1. Lertdumrongluk P, Streja E, Rhee CM. et al. Dose of hemodialysis and survival: a marginal structural model analysis. Am J Nephrol 2014; 39: 383–391 - PMC - PubMed
    1. Panichi V, Rizza GM, Paoletti S. et al.; on behalf of the RISCAVID Study Group. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008; 23: 2337–2343 - PubMed
    1. Locatelli F, Karaboyas A, Pisoni RL. et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘real-world’ comparison from the DOPPS. Nephrol Dial Transplant 2017; 33: 683–689 - PMC - PubMed